Key points from article :
Neurotrack, a startup based in Redwood City, has raised $21 million in Series C funding to further develop its innovative cognitive tests aimed at detecting early signs of dementia, particularly Alzheimer’s disease. The company’s eye-tracking technology, which monitors users' eye movements as they view images on a screen, offers a non-invasive method to establish a memory health baseline and track cognitive changes over time. This platform is backed by decades of neuroscience research and aims to identify Alzheimer's onset with impressive accuracy.
The new funding will help Neurotrack expand its memory health program globally, advancing its mission to transform cognitive health management. The company’s browser- and app-based system not only detects early cognitive impairments but also provides lifestyle recommendations, including exercise, diet, and brain games, to help users preserve their memory. Neurotrack’s method has shown success in improving cognition among at-risk individuals, and its growing adoption in clinical settings and partnerships, including with insurance providers in Japan, highlights its potential as a scalable solution.
Neurotrack’s platform, which builds on extensive research from Emory University, is designed to be accessible and user-friendly, allowing for at-home assessments and regular monitoring. With funding from investors like Khosla Ventures and Sozo Ventures, as well as grants from organizations like the National Institutes of Health, Neurotrack is positioning itself as a leader in early detection and intervention for Alzheimer’s disease.
